DOCSLIB.ORG

Annu Al Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annu Al Review THE WELLCOME TRUST THE WELLCOME THE WELLCOME TRUST THE WELLCOME TRUST ANNUAL REVIEW ANNUAL REVIEW ANNUAL 1999/2000 1 October 1999 1 October1999 _ 30 September2000 The Wellcome Trust is an independent research-funding charity, established under the will of Sir Henry Wellcome in 1936.It is funded from a private endowment, which is managed with long-term stability and growth in mind. Its mission is to foster and promote research with the aim of improving human and animal health. Its work covers four areas: Knowledge improving our understanding of human and animal biology in health and disease, and of the past and present role of medicine in society. Resources providing exceptional researchers with the infrastructural and career support they need to fulfil their potential. Translation ensuring maximum health benefits are gained from biomedical research. Public engagement raising awareness of the medical, ethical and social implications of biomedical science. CONTENTS Highlights of the year 2 Director’s Introduction 4 Planning for the Future 6 PART 1 MAKING A DIFFERENCE 1999–2000 Knowledge Base 8 Resources 14 Translation 20 Public Engagement 26 PART 2 RESEARCH REPORTS Making faces 32 Tipping the balance 35 Starfish and mousetraps 36 The hidden danger 40 Capping it all 43 Thinking inside the box 44 Why art? 48 The past is before us 50 Birth of a cell 54 Breaking the cycle 57 Cross-talking networks 60 PART 3 A YEAR IN THE TRUST UK Funding 64 Clinical and Careers 66 Centres and Indirectly Managed Major Initiatives 68 International Funding 70 Directly Managed Major Initiatives 73 Medicine, Society and History 74 Catalyst BioMedica Ltd 77 Financial Summary 78 The Board of Governors and Executive Board 80 Advisory Committees 81 Highlights of the year KNOWLEDGE BASE RESOURCES Genomics Infrastructure The first draft of the human genome is The Trust awards £124 million and £71.8 million completed by the Wellcome Trust Sanger in the second and third rounds of the Joint Centre and international partners, and the Infrastructure Fund, a £750 million partnership achievement announced to all at the between the UK Government and the Wellcome Wellcome Trust on 26 June 2000. Trust to inject much-needed funds into the UK Sequencing of the Salmonella typhi (typhoid) university research infrastructure. and Yersinia pestis (plague) genomes is also The Trust pledges £225 million to the £1 billion completed at the Sanger Centre. Science Research Investment Fund, established by the UK Government in 2000. Post-genomics Data released by the SNP Consortium – a £30 Careers million collaboration between the Trust and a Seven new four-year PhD Training Programmes number of pharmaceutical and technological are awarded to universities in December 1999, companies – are used to create a high- bringing the number of programmes to 12. resolution map of genetic markers. The Wellcome Trust publishes the results of two The Trust invests in a new microarray facility at surveys of past and present Trust-funded PhD the Sanger Centre, in partnership with the students in March 2000. Imperial Cancer Research Fund. The Trust publishes the results of an investigation The Trust begins planning a major new initiative into grant application behaviour to examine why in functional genomics, Integrated Thematic fewer women than men apply for grants. Programmes, which aims to bring together Centres research groups from different disciplines to The Wellcome Trust and Cancer Research address a single biological question. Campaign Institute of Cancer and International Developmental Biology in Cambridge and the Seven awards totalling £12 million are made Wellcome Trust Centre for Cell-Matrix Research to trilateral research collaborations in the first at the University of Manchester are reviewed round of the Wellcome Trust–Burroughs and their core funding is renewed. Wellcome Fund Infectious Diseases Initiative. International A second competition is launched in 2000. The Trust’s international units in Kenya and History of medicine South-East Asia receive site visits and are The Trust publishes a survey appraising the awarded funding for another five years. development of history of medicine in the The Wellcome Trust Centres for Research UK over the last 30 years. in Clinical Tropical Medicine in the UK are The Academic Unit – formerly part of the also renewed. Wellcome Institute for the History of Medicine History of medicine – is transferred to University College London The Wellcome Trust’s History of Medicine (UCL) and becomes the Wellcome Trust Library celebrates its 50th anniversary in Centre for the History of Medicine at UCL. December 1999. Professor Hal Cook from the University of The History of Medicine Library joins with the Wisconsin at Madison, USA, is recruited as Information Service and the Medical Director of the Centre at UCL in June 2000. Photographic and Film and Video Libraries to Medicine in society form the Wellcome Library for the History and The Trust’s Biomedical Ethics Programme calls Understanding of Medicine. for proposals for research into the ethical, legal The Trust adds a Senior Research Fellowship and social implications of pharmaco- scheme to its History of Medicine Programme genetics and biological sample collections. and makes two awards. 2 HIGHLIGHTS OF THE YEAR PUBLIC ENGAGEMENT Company history Surveys and consultations Glaxo Wellcome (now GlaxoSmithKline) Science and the Public, a nationwide survey of donates the company records of the pharma- public attitudes to science sponsored by the ceutical company, the Wellcome Foundation Ltd, Wellcome Trust and the Office of Science and to the Trust, bringing all the personal and Technology, is published. business archives of Sir Henry Wellcome and The Wellcome Trust and Medical Research his partner, Silas Mainville Burroughs, together Council commission research to discover the under one roof. public’s views on the proposed UK Population Professor Roy Church and Dr Tilli Tansey Biomedical Collection. unearth the account book of Burroughs Wellcome & Co., documenting its financial Science Centres activity between 1880 and 1940. Five of the eight Science Centres, to which the Trust has contributed £45 million, open TRANSLATION in London, Manchester, Newcastle, Bristol and Dundee. Dissemination The Wellcome Wing of the Science Museum is The Trust awards £8 million to a collaboration opened by the Queen on 27 June 2000. between the Sanger Centre and European Bioinformatics Institute (EMBL-EBI – part of the Art and drama European Molecular Biology Laboratory) to A total of £200 000 is awarded to 11 innovative develop Ensembl, an annotated view of science–art partnerships in the 2000 sciart the human genome. competition. The Trust’s Tropical Medicine Resource launches Three Trust-sponsored plays perform at the four new CD-ROMs in its ‘Topics in Edinburgh Fringe Festival: The Idiot, Learning to International Health’ series of multimedia Love the Grey, and Safe Delivery. teaching materials. A new Science on Stage and Screen compe- Exploitation tition – seeking to engage the public’s interest Six awards are made by the Catalyst BioMedica in biomedical science or health through the Development Fund, set up to facilitate the use of drama, film/video and multimedia – exploitation of Trust-funded research. is approved. Clinical research Schools The Trust holds a workshop to encourage The Trust commissions the Institute of debate on research issues in complementary Education to investigate how teachers approach and alternative medicine, and presents a report the social, legal and ethical implications of on the workshop to the House of Lords Select science in the classroom. Committee on Science and Technology. Seventy-seven PhD students spend four days International working alongside teachers and pupils in schools The Trust funds an international meeting in as part of the Researchers in Residence scheme. Liverpool to discuss the implementation of Two new issues of the LabNotes series – ‘Down Lapdap, a new antimalarial drug developed at at the Pharm’ and ‘Beyond the Genome’ – its Kenyan unit. are published. HIGHLIGHTS OF THE YEAR 3 Director’s introduction The future within fully committed to such principles, as More than ten years ago, I discussed with my enshrined in the Bermuda agreement of 1996, colleagues the logistics and philosophy of a and the Trust’s grant of £8 million to the huge new undertaking, the Human Genome Ensembl website will help the development Project. For the logistics, our feeling then was of this free-access Internet ‘gateway’ to that the project was entirely feasible and the genome. would bring enormous benefits in the future The UK is fortunate to have so many talented should it succeed. But perhaps more inter- and innovative scientists, and it is essential that esting were the philosophical discussions we back them with the high-quality resources about how the human genome would change and facilities they deserve.Through the Joint our views of science and of what it means to Infrastructure Fund (JIF) – a partnership be human. It brings to mind a comment by the between the Trust and the UK Government – French ocean explorer Jacques Cousteau: we have been working to address the infra- “What is a scientist after all? It is a curious structure problems that had become apparent man looking through a keyhole, the keyhole of in the UK universities.We have now nature, trying to know what’s going on”. Once completed all the funding rounds of the JIF, and the human genome is completed, the curious the Trust has committed £300 million to 56 geneticist will have stopped looking through awards that will provide new buildings and the keyhole and will have stepped through the equipment for researchers all over the door to gaze upon human inheritance. country.The awards of the first year of the The announcement in June 2000 that the Fund are already bearing fruit, with new milestone of the first draft of the human equipment installed and construction genome sequence had been reached was – continuing apace.
Load more

Recommended publications
  • Simvastatin Causes Pulmonary Artery Relaxation by Blocking Smooth Muscle ROCK and Calcium Channels: Evidence for an Endothelium-Independent Mechanism
    RESEARCH ARTICLE Simvastatin causes pulmonary artery relaxation by blocking smooth muscle ROCK and calcium channels: Evidence for an endothelium-independent mechanism 1,2 1,3 1 1 1 Mais Absi , Basma G. Eid , Nick Ashton , George Hart , Alison M. GurneyID * 1 Faculty of Biology Medicine and Health, University of Manchester, Core Technology Facility level, a1111111111 Manchester, United Kingdom, 2 Cardiovascular Sciences, Kings College London, London, United Kingdom, 3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, a1111111111 Saudi Arabia a1111111111 a1111111111 * [email protected] a1111111111 Abstract Simvastatin reduces pulmonary arterial pressure and right ventricular hypertrophy in animal OPEN ACCESS models of pulmonary arterial hypertension (PAH) and is thought to restore endothelial dys- Citation: Absi M, Eid BG, Ashton N, Hart G, Gurney function. In vivo effects of drugs are complicated by several factors and little is known of the AM (2019) Simvastatin causes pulmonary artery relaxation by blocking smooth muscle ROCK and direct effects of statins on pulmonary arteries. This study investigated the direct effects of calcium channels: Evidence for an endothelium- simvastatin on pulmonary arteries isolated from rats with or without monocrotaline-induced independent mechanism. PLoS ONE 14(8): PAH. Simvastatin suppressed contractions evoked by the thromboxane A2 receptor agonist e0220473. https://doi.org/10.1371/journal. U46619 (30 nM), the α ±adrenergic agonist phenylephrine (5 μM) and KCl (50 mM) by pone.0220473 1 ~50% in healthy and diseased arteries, but did not reduce contraction evoked by sarco/ Editor: Alexander G. Obukhov, Indiana University endoplasmic reticulum ATPase blockers. It relaxed hypertensive arteries in the absence of School of Medicine, UNITED STATES stimulation.
    [Show full text]
  • Physiologynews
    PHYSIOLOGYNEWS winter 2005 | number 61 Meetings UCL Images of Oxford Bristol revisited Also featuring: Physiology in space Richard Naftalin’s ‘desert island’ selection Cutting through the melatonin hype Reflections of a ex-Chair Letter from Russia What turned us on to physiology Winter books special A publication of The Physiological Society OXFORD FOCUSED MEETING Ion channels, genes and regulation in smooth muscle 5-7 September 2005 More photos and a report from the Oxford Focused Meeting appear on p. 5 (photos by Prem Kumar and Roger Thomas) PHYSIOLOGYNEWS Editorial 3 Movement neuroscience at UCL Philip Harrison 4 Ion channels, genes and regulation in smooth The Society’s dog. ‘Rudolf Magnus gave muscle David Beech, Anant Parekh, Phil Aaronson 5 me to Charles Sherrington, who gave me ‘Stan-power’ 7 to Henry Dale, who gave me to the Judy Harris Physiological Society in October 1942’ Bristol revisited Austin Elliott 8 My 10 key papers 10 My top 10 papers on biological salt, water and sugar transport Published quarterly by the Physiological Society Richard Naftalin Contributions and Queries Executive Editor A week in the life of... 14 Linda Rimmer A short month in the life of the Vice Chair Ian McGrath The Physiological Society Publications Office P.O. Box 502 What turned me on to physiology? Thelma Lovick, 15 Cambridge CB1 0AL UK Bill Winlow, Austin Elliott Tel: +44 (0)1223 400180 Letter from...Russia Evgeny Nikolsky, Ellya Bukharaeva 17 Fax: +44 (0)1223 246858 Email: [email protected] The Society web server: http://www.physoc.org Physiology
    [Show full text]
  • KV7 Potassium Channels: a Focus on Human Intra-Pulmonary Arteries
    KV7 potassium channels: A focus on human intra-pulmonary arteries A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Life Sciences 2015 Sean Brennan 1 List of contents Chapter 1 : Introduction ........................................................................................................ 15 1.1 Anatomy and physiology of the lungs .......................................................................... 15 1.2 Pulmonary artery structure ......................................................................................... 15 1.3 Pulmonary hypertension .............................................................................................. 16 1.3.1 Definition .............................................................................................................. 16 1.3.2 Characteristics ....................................................................................................... 17 1.3.3 Classification ......................................................................................................... 17 1.3.4 Treatment ............................................................................................................. 19 1.4 Regulation of the pulmonary vasculature.................................................................... 21 1.4.1 Neuronal regulation .............................................................................................. 21 1.4.2 Humoral regulation ..............................................................................................
    [Show full text]
  • QUARTERLY BULLETIN Contents
    THE BRITISH SOCIETY FOR CARDIOVASCULAR RESEARCH QUARTERLY BULLETIN July 1996 Volume 9 No. 3 Contents Editorial 3 BSCR Events Diary i 3 Secretary's Column 4 BSCR Workshop Report The Experimental and Therapeutic Gene Transfer and Antisense Strategies for Cardiovascular Disease 5 Meeting Report First Joint National Vascular Meeting: Diabetic Angiopathy 6 Job Advert Postdoctoral Electrophysiologist 7 Forthcoming Meetings 7' Nominations for BSCR Committee 8 Software Review: Cellular Mechanisms in Cardiac Physiology Functional Anatomy of the Heart 10 BSCR Quarterly Bulletin Deadlines 11 British Heart Foundation Awards January/June 1996 12 BSCR Autumn Meeting Poster Mediators in Cardiovascular Disease 20 Registered Charity Number: 1011141 Supported by an educational grant from: CARDIOVASCULAR THE BRITISH SOCIETY FOR CARDIOVASCULAR RESEARCH Quarterly Bulletin Editors Committee Dr T. Jeff Allen Dr. Gary F Baxter Department of Pharmacology The Hatter Institute of Cardiovascular Studies Royal Free Hospital School of Medicine Department of Academic & Clinical Cardiology Rowland Hill Street University College Hospital London NW3 2PF Grafton Way Tel. 0171-794 0500 ext. 5751 London WCIE 6DB Fax. 0171-794 6854 Tel: 0171 380 9888 e-mail: [email protected] Fax: 0171 388 5095 e-mail: [email protected] Dr Kathryn O. Ryder Department of Cardiovascular Medicine Dr. Michael J Curtis John Radcliffe Hospital, Oxford OX3 9DU Pharmacology Group Tel. 01865-220 428/136 Biomedical Siences Division Fax. 01865-221 977 Kings College London e-mail: [email protected] Manresa Road London SW3 6LX Chairman Dr Peter Cummins Dr. Suzanna Hardman Dept. of Physiology Hatter Institute of Cardiovascular Studies Molecular Cardiology Unit University College London Medical School The Medical School, University of Birmingham Grafton Way Birmingham B15 2TJ London WCl 6DB Tel: 0121-414 6896 Tel.
    [Show full text]
  • 27Th Northern Cardiovascular Research Group Meeting UNIVERSITY of LEEDS
    27th Northern Cardiovascular Research Group Meeting UNIVERSITY OF LEEDS Committee Organiser: Dr. Hannah M. Kirton Tuesday 30th April 2019 The Great Hall and Parkinson Court University of Leeds Woodhouse Lane, LS2 9JT 1 27th Annual Northern Cardiovascular Research Group Meeting Tuesday 30th April 2019 Welcome to the 27th Annual Northern Cardiovascular Research Group Meeting, which is being held at the University of Leeds. We hope you find the day both beneficial and stimulating. The Northern Cardiovascular Research Group meeting provides a stimulating arena for high calibre scientific content, informative and enjoyable discussions, collaborative opportunities and a relaxed atmosphere within a cardiovascular research community. This annual event has brought together those with an interest in the cardiovascular system since 1991 at the University of Leeds, but has moved a long way from its initial roots in the North of England, and now includes researchers from Bristol, Northern Ireland and Scotland. The NCRG has also proudly recognised and supported students, early career researchers, and more senior researchers, to present their work to a friendly environment, providing a stimulating arena for discussion; and welcomed a New&Notable platform at the Leeds 2016 meeting. This year we also highlight the cardiovascular research of Professor Clive Orchard (formally a University of Leeds academic member and founding organiser of this conference) with research recognition throughout the day. Dr Hannah M. Kirton Cardiovascular and Ion channel Postdoctorate Researcher 2 Sponsors We are very grateful and honoured to receive generous support and funding from the British Heart Foundation, University of Leeds, University of Bristol and Badrilla to allow us to hold this honorary 2019 research meeting.
    [Show full text]
  • University of Strathclyde Calendar 2010-11 Part 1 General Regulations
    University of Strathclyde Calendar 2010-11 Part 1 General Regulations ISBN 1 85098 590 2 ISSN 0305-3180 © University of Strathclyde 2010 The University of Strathclyde is a registered trademark The Calendar is published on-line in four parts: Part 1 contains the University Charter, Statutes and Ordinances, together with Regulations 1-7 and an Appendix (History of the University, Armorial Bearings, University Chairs and Honorary Graduates). Part 2 contains Regulations 15-17 covering the course regulations for undergraduate and integrated master’s degrees of the four Faculties and elective classes. Part 3 contains Regulations 19-30 covering the postgraduate, continuing education, sub-degree courses and prize regulations of the four Faculties. This edition of the Calendar is as far as possible up to date and accurate at 15 August 2010. Changes and restrictions are made from time to time and the University reserves the right to add, amend or withdraw courses and facilities, to restrict student numbers and to make any other alterations, as it may deem necessary and desirable. Changes are published by incorporation in the next edition of the University Calendar. Any queries about the contents of the University Calendar should be directed to the Editor of the University Calendar, Corporate Services, University of Strathclyde, Glasgow G1 1XQ (Telephone 0141 548 4967). Official Publications Annual Report The University Review is available free of charge from The Publications Officer, University of Strathclyde, 16 Richmond Street, Glasgow G1 1XQ
    [Show full text]
  • Pharmacology Education and Training in Europe
    Society News Editorial Team Contents: Welcome to the first Pharmacology Editor-in-Chief Ephar 2008 message from the President 3 Matters! Kate Baillie View from Angel Gate 4 The BPS will be hosting the EPHAR 2008 Congress in Manchester next month, to Managing Editor Younger Members News 5 honour this auspicious event the first Pharmacology Education and Training in Europe 6 Hazel O’Mullan issue of Pharmacology Matters has a BSF update on Revision of EU Directive 86/609 9 distinctly European ‘flavour.’ This issue Editorial Board includes amongst others an interview EU Innovative Medicines Initiative 10 Simon Constable with a Spanish BPS Diploma student and BPS Meetings Report 12 an article detailing how pharmacologists Stephanie Francis High Throughput Pharmacology, Focused Meeting 13 are ‘created’ in several countries across Jude Hall the continent. We hope you enjoy the European Diploma Student Profile 14 new look newsletter and welcome your Sarra Laycock Diploma Workshop report 15 comments, which could find their way into ‘Letters to the Editor’, see page 21! Ramona Scotland UKRC SET’s Annual Conference 16 Adam Smith EACPT 2009 18 BPS Membership open to EPHAR delegates Cherry Wainwright BPS Response to consultation on EU Directive Information on Patients 19 Join over 2000 British Pharmacological Letters to Editor 21 Society (BPS) members worldwide and We welcome receive a host of benefits including free contributions from Welcome to the Congratu- online access to all BPS publications, our readers, all following, who lations to free BPS meeting registration, access to suggestions should have been elect- Professor V. education courses and funding oppor- be e-mailed to the ed to the Society Craig Jordan, tunities.
    [Show full text]
  • Pulmonary Vasoconstrictor Action of KCNQ Potassium Channel Blockers Shreena Joshi1,2, Prabhu Balan1 and Alison M Gurney*1,2
    Respiratory Research BioMed Central Research Open Access Pulmonary vasoconstrictor action of KCNQ potassium channel blockers Shreena Joshi1,2, Prabhu Balan1 and Alison M Gurney*1,2 Address: 1Department of Physiology & Pharmacology, University of Strathclyde, 27 Taylor street, Glasgow G4 0NR, UK and 2Faculty of Life Sciences, University of Manchester, Floor 2, Core Technology Facility, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK Email: Shreena Joshi - [email protected]; Prabhu Balan - [email protected]; Alison M Gurney* - [email protected] * Corresponding author Published: 20 February 2006 Received: 01 November 2005 Accepted: 20 February 2006 Respiratory Research 2006, 7:31 doi:10.1186/1465-9921-7-31 This article is available from: http://respiratory-research.com/content/7/1/31 © 2006 Joshi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: KCNQ channels have been widely studied in the nervous system, heart and inner ear, where they have important physiological functions. Recent reports indicate that KCNQ channels may also be expressed in portal vein where they are suggested to influence spontaneous contractile activity. The biophysical properties of K+ currents mediated by KCNQ channels resemble a current underlying the resting K+ conductance and resting potential of pulmonary artery smooth muscle cells. We therefore investigated a possible role of KCNQ channels in regulating the function of pulmonary arteries by determining the ability of the selective KCNQ channel blockers, linopirdine and XE991, to promote pulmonary vasoconstriction.
    [Show full text]
  • Membership of RAE2008 Panels
    Membership of RAE2008 panels November 2007 Ref RAE 03/2007 Membership of RAE2008 panels To Heads of HEFCE-funded higher education institutions Heads of HEFCW-funded higher education institutions Heads of SFC-funded higher education institutions Heads of universities in Northern Ireland Of interest to those Research assessment, Research policy, responsible for Planning Reference RAE 03/2007 Publication date November 2007 Enquiries to Raegan Hiles or Davina Madden tel 0117 931 7267 e-mail [email protected] Executive summary Purpose 1. This document lists the membership of the main and sub-panels for the 2008 Research Assessment Exercise (RAE2008). The panels will assess the quality of research in submissions to RAE2008. Key points 2. For the purpose of RAE2008, each academic discipline is assigned to one of 67 units of assessment (UOAs). There is a two-tier panel system: 67 sub-panels of experts, one for each UOA, work under the guidance of 15 main panels. Under each main panel are broadly cognate disciplines whose subjects have similar approaches to research. 3. Panel members are experts drawn from higher education institutions (HEIs) and the wider research community, and are nominated by subject associations and other stakeholder organisations. Each main panel and sub-panel has stipulated criteria and working methods that they will adhere to in making assessments: these were published in January 2006 as RAE 01/2006: RAE2008: Panel criteria and working methods. 4. This list of panel membership is correct at the time of going to print. Should any member retire from the panel or be replaced during 2008, we will update the electronic list available at www.rae.ac.uk under ‘Panels’.
    [Show full text]
  • Springer A++ Viewer
    PublisherInfo PublisherName : BioMed Central PublisherLocation : London PublisherImprintName : BioMed Central 130591474-760XGenome BiologyGenome BiolLife SciencesAnimal Genetics and GenomicsHuman GeneticsPlant Genetics & GenomicsMicrobial Genetics and GenomicsBioinformaticsEvolutionary BiologyBiomedical and Life Sciences221211343 CoverDate : 2001–12– The Author(s)2001 The genome has landed - let the debate begin ArticleInfo ArticleID : 3976 ArticleDOI : 10.1186/gb-spotlight-20010212-01 ArticleCitationID : spotlight-20010212-01 ArticleSequenceNumber : 47 ArticleCategory : Research news ArticleFirstPage : 1 ArticleLastPage : 2 RegistrationDate : 2001–02–12 ArticleHistory : OnlineDate : 2001–02–12 ArticleCopyright : BioMed Central Ltd2001 ArticleGrants : ArticleContext : 130592211 Pete Moore Email: [email protected] LONDON Sequencing the human genome has been likened to landing on the moon. Two decades ago most people laughed at the prospect. One decade ago the task looked achievable but would be unbelievably slow. Then, a couple of years back we had some 5% of the code and the first draft. In 1998, when Craig Venter set up his own research unit and privatised the sequencing program, he fired a starting pistol. While private investors poured money into Venter's Celera Genomics, governments and the Wellcome Trust were forced to divert streams of cash into the race. The publicly funded Human Genome Project (HGP) was eager to publish a sequence of the genome, and quash any attempt to gain ownership of the information via patenting. The result has been two-fold, says Denis Alexander, head of the Molecular Immunology Programme at the Babraham Institute outside Cambridge, UK. First, having two separate efforts has undeniably accelerated the pace of research, knocking a couple of years off the anticipated time-scale. But second, he like many believes that the high-profile scrap has probably damaged public confidence or public perceptions of science.
    [Show full text]
  • Pulmonary Vasoconstrictor Action of KCNQ Potassium Channel Blockers
    Joshi, Shreena and Balan, Prabhu and Gurney, Alison M. (2006) Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respiratory Research, 7 (31). ISSN 1465-9921 http://eprints.cdlr.strath.ac.uk/3121/ Strathprints is designed to allow users to access the research output of the University of Strathclyde. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in Strathprints to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profitmaking activities or any commercial gain. You may freely distribute the url (http://eprints.cdlr.strath.ac.uk) of the Strathprints website. Any correspondence concerning this service should be sent to The Strathprints Administrator: [email protected] Respiratory Research BioMed Central Research Open Access Pulmonary vasoconstrictor action of KCNQ potassium channel blockers Shreena Joshi1,2, Prabhu Balan1 and Alison M Gurney*1,2 Address: 1Department of Physiology & Pharmacology, University of Strathclyde, 27 Taylor street, Glasgow G4 0NR, UK and 2Faculty of Life Sciences, University of Manchester, Floor 2, Core Technology Facility, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK Email: Shreena Joshi - [email protected]; Prabhu Balan - [email protected]; Alison M Gurney* - [email protected] * Corresponding author Published: 20 February 2006 Received: 01 November 2005 Accepted: 20 February 2006 Respiratory Research 2006, 7:31 doi:10.1186/1465-9921-7-31 This article is available from: http://respiratory-research.com/content/7/1/31 © 2006 Joshi et al; licensee BioMed Central Ltd.
    [Show full text]
  • EPHAR2008 2Nd Announcement
    An Invitation to Participate in EPHAR 2008 On behalf of our colleagues in EPHAR and the British Arthur Weston Pharmacological Society, who are hosting this event, it is our President, Federation of great pleasure to extend a personal invitation to participate European Pharmacological in EPHAR 2008, which will be held in Manchester from 13th to Societies 17th July 2008. Over the 4-day meeting, basic and clinical pharmacologists, together with related bioscientists from EPHAR’s 24 affi liated Pharmacological Societies with a total of 12,000 members, will enjoy an unrivalled scientifi c feast. The programme itself is unparalleled; free scientifi c communications together with plenary lectures and cutting-edge symposia with subject- leading speakers will ensure that EPHAR 2008 is the most important international pharmacological event of the year. EPHAR 2008 will take place at University Place, Manchester University’s brand new International Conference Centre with superb facilities for exhibitors and delegates alike. Set in the heart of the UK’s largest single-site University, with an income of £514 million and 10,400 staff, no organisation whose business encompasses the broad range of products and services used by today’s pharmacologists can afford to miss Jeffrey Aronson out on a unique opportunity to establish important new President, British contacts and consolidate existing ones. Pharmacological Society Manchester itself is easily reached by road, rail or air. Steeped in the history of the Industrial Revolution, the city offers vibrant cultural, leisure and sporting facilities for evening entertainment. The Congress Dinner, to which all participants are warmly invited, will be held at Old Trafford, home of the world-famous Manchester United Football Club.
    [Show full text]